Literature DB >> 8385309

Reactions of pediatricians to a new Centers for Disease Control recommendation for universal immunization of infants with hepatitis B vaccine.

G L Freed1, W C Bordley, S J Clark, T R Konrad.   

Abstract

Despite immunization programs targeting high-risk groups, the incidence of hepatitis B has risen 37% over the last decade with 300,000 new infections and 5000 related deaths now occurring annually in the United States. As a new strategy to control the spread of hepatitis B, the Advisory Committee on Immunization Practices of the Centers for Disease Control (CDC) recommended in November 1991 universal hepatitis B immunization of infants. Details were published in an addendum to Morbidity and Mortality Weekly Report. There was no other federal effort to disseminate this recommendation. On February 14, 1992, the American Academy of Pediatrics (AAP) issued a similar recommendation. The time between the CDC and AAP recommendations presented the opportunity to determine the singular effect on clinical practice of the CDC's dissemination effort. The purpose of this study was to assess (1) the effectiveness of the CDC in disseminating a new immunization recommendation, (2) the effect of the new recommendation on clinical practice, and (3) the degree to which noneconomic barriers may affect adoption of universal hepatitis B immunization. All 778 pediatricians in North Carolina were surveyed by mail 2 to 3 months after publication of the new CDC recommendation. Descriptive statistics, chi 2 analysis, and logistic regression were used to assess the relationship of variables hypothesized to predict physician awareness of and/or agreement with the new recommendation. The response rate was 78%. Although 82% of pediatricians who administer immunizations were aware of the new recommendation, only 32% believed it was warranted in their practices.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8385309

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

1.  Adopting immunization recommendations: a new dissemination model.

Authors:  G L Freed; D E Pathman; T R Konrad; V A Freeman; S J Clark
Journal:  Matern Child Health J       Date:  1998-12

Review 2.  Update on diagnosis, management, and prevention of hepatitis B virus infection.

Authors:  F J Mahoney
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

3.  Progress in coverage with hepatitis B vaccine among US children, 1994-1997.

Authors:  H R Yusuf; V G Coronado; F A Averhoff; E F Maes; L E Rodewald; M P Battaglia; F J Mahoney
Journal:  Am J Public Health       Date:  1999-11       Impact factor: 9.308

4.  Canadian family physicians' and paediatricians' knowledge, attitudes and practices regarding A(H1N1) pandemic vaccine.

Authors:  Eve Dubé; Vladimir Gilca; Chantal Sauvageau; Nicole Boulianne; François D Boucher; Julie A Bettinger; Shelly McNeil; Ian Gemmill; France Lavoie; Manale Ouakki
Journal:  BMC Res Notes       Date:  2010-04-14

5.  Prevalence and correlates of HIV, syphilis, and hepatitis knowledge among intrapartum patients and health care providers in Kabul, Afghanistan.

Authors:  C S Todd; M Ahmadzai; F Atiqzai; J M Smith; S Miller; P Azfar; H Siddiqui; S A S Ghazanfar; S A Strathdee
Journal:  AIDS Care       Date:  2009-01

6.  Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix B and Shanvac B in high risk infants born to HBsAg positive mothers in India.

Authors:  Vijayakumar Velu; Subhadra Nandakumar; Saravanan Shanmugam; Suresh-Sakharam Jadhav; Prasad-Suryakant Kulkarni; Sadras-Panchatcharam Thyagarajan
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

7.  Medical care of hepatitis B among Asian American populations: perspectives from three provider groups.

Authors:  Jessica P Hwang; Aimee K Roundtree; Joan C Engebretson; Maria E Suarez-Almazor
Journal:  J Gen Intern Med       Date:  2010-01-05       Impact factor: 5.128

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.